475 related articles for article (PubMed ID: 17314145)
21. [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].
Chronopoulos A; Pleyer U; Mockenhaupt M
Klin Monbl Augenheilkd; 2012 May; 229(5):534-9. PubMed ID: 22592345
[TBL] [Abstract][Full Text] [Related]
22. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome.
Kim DH; Yoon KC; Seo KY; Lee HS; Yoon SC; Sotozono C; Ueta M; Kim MK
Ophthalmology; 2015 Feb; 122(2):254-64. PubMed ID: 25262319
[TBL] [Abstract][Full Text] [Related]
23. "Triple-TEN" in the treatment of acute ocular complications from toxic epidermal necrolysis.
Tomlins PJ; Parulekar MV; Rauz S
Cornea; 2013 Mar; 32(3):365-9. PubMed ID: 22677638
[TBL] [Abstract][Full Text] [Related]
24. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset.
Araki Y; Sotozono C; Inatomi T; Ueta M; Yokoi N; Ueda E; Kishimoto S; Kinoshita S
Am J Ophthalmol; 2009 Jun; 147(6):1004-11, 1011.e1. PubMed ID: 19285657
[TBL] [Abstract][Full Text] [Related]
25. Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat.
Bang D; Shah T; Thakker D; Shah Y; Raval AD
Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):384-95. PubMed ID: 22374707
[TBL] [Abstract][Full Text] [Related]
26. Acute renal failure and its risk factors in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Hung CC; Liu WC; Kuo MC; Lee CH; Hwang SJ; Chen HC
Am J Nephrol; 2009; 29(6):633-8. PubMed ID: 19155617
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis and recent therapeutic trends in Stevens-Johnson syndrome and toxic epidermal necrolysis.
Khalili B; Bahna SL
Ann Allergy Asthma Immunol; 2006 Sep; 97(3):272-80; quiz 281-3, 320. PubMed ID: 17042130
[TBL] [Abstract][Full Text] [Related]
28. The management of severe ocular complications of stevens-johnson syndrome and toxic epidermal necrolysis.
Sotozono C; Ueta M; Kinoshita S
Arch Dermatol; 2009 Nov; 145(11):1336-7; author reply 1337-8. PubMed ID: 19917974
[No Abstract] [Full Text] [Related]
29. Chronic Ocular Complications of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: The Role of Systemic Immunomodulatory Therapy.
Chang VS; Chodosh J; Papaliodis GN
Semin Ophthalmol; 2016; 31(1-2):178-87. PubMed ID: 26959145
[TBL] [Abstract][Full Text] [Related]
30. Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries.
Saka B; Barro-Traoré F; Atadokpédé FA; Kobangue L; Niamba PA; Adégbidi H; Yedomon HG; Traoré A; Pitché VP
Int J Dermatol; 2013 May; 52(5):575-9. PubMed ID: 23330601
[TBL] [Abstract][Full Text] [Related]
31. Prosthetic replacement of the ocular surface ecosystem as treatment for ocular surface disease in patients with a history of Stevens-Johnson syndrome/toxic epidermal necrolysis.
Papakostas TD; Le HG; Chodosh J; Jacobs DS
Ophthalmology; 2015 Feb; 122(2):248-53. PubMed ID: 25282251
[TBL] [Abstract][Full Text] [Related]
32. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.
Kardaun SH; Jonkman MF
Acta Derm Venereol; 2007; 87(2):144-8. PubMed ID: 17340021
[TBL] [Abstract][Full Text] [Related]
33. [Ophthalmic manifestations after Lyell and Stevens-Johnson syndromes].
Mouafik SB; Hocar O; Akhdari N; Amal S; Belghmaidi S; Ennassiri W; Hajji I; Moutaouakil A
Ann Dermatol Venereol; 2015; 142(6-7):393-8. PubMed ID: 25896732
[TBL] [Abstract][Full Text] [Related]
34. The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies.
Lee HY; Dunant A; Sekula P; Mockenhaupt M; Wolkenstein P; Valeyrie-Allanore L; Naldi L; Halevy S; Roujeau JC
Br J Dermatol; 2012 Sep; 167(3):555-62. PubMed ID: 22639874
[TBL] [Abstract][Full Text] [Related]
35. Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis.
Hosaka H; Ohtoshi S; Nakada T; Iijima M
J Dermatol; 2010 May; 37(5):407-12. PubMed ID: 20536645
[TBL] [Abstract][Full Text] [Related]
36. In vivo confocal microscopic evaluation of corneal changes in chronic Stevens-Johnson syndrome and toxic epidermal necrolysis.
Vera LS; Gueudry J; Delcampe A; Roujeau JC; Brasseur G; Muraine M
Cornea; 2009 May; 28(4):401-7. PubMed ID: 19411958
[TBL] [Abstract][Full Text] [Related]
37. Fatal toxic epidermal necrolysis associated with minoxidil.
Karaoui LR; Chahine-Chakhtoura C
Pharmacotherapy; 2009 Apr; 29(4):460-7. PubMed ID: 19323621
[TBL] [Abstract][Full Text] [Related]
38. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis.
Ukponmwan CU; Njinaka I; Ehimiyen ET
Trop Doct; 2010 Jul; 40(3):167-8. PubMed ID: 20555046
[TBL] [Abstract][Full Text] [Related]
39. Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up.
Lee HY; Walsh SA; Creamer D
Br J Dermatol; 2017 Oct; 177(4):924-935. PubMed ID: 28144971
[TBL] [Abstract][Full Text] [Related]
40. Oculocutaneous manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum.
Wilkins J; Morrison L; White CR
Dermatol Clin; 1992 Jul; 10(3):571-82. PubMed ID: 1617814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
